The value of new drugs for advanced prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The value of new drugs for advanced prostate cancer

Published:2021-06 Issue:18 Volume:127 Page:3457-3465
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Howard David H.¹²^ORCID,Quek Ruben G. W.³,Fox Kathleen M.⁴,Arondekar Bhakti⁵^ORCID,Filson Christopher P.²⁶^ORCID

Affiliation:

1. Department of Health Policy and Management Emory University Atlanta Georgia

2. Winship Cancer Institute, Emory Healthcare Atlanta Georgia

3. Pfizer, Inc San Francisco California

4. Strategic Healthcare Solutions, LLC Aiken South Carolina

5. Pfizer, Inc Collegeville Pennsylvania

6. Department of Urology Emory University Atlanta Georgia

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33662

Reference40 articles.

1. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

2. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration

3. Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress

4. The Strength of Association Between Surrogate End Points and Survival in Oncology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer;Urology Practice;2024-05

2. Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic “Advances”;Journal of Urology;2024-02

3. Pharmacists’ approach to oncology medicine shortages: results of a cross-sectional survey in Pakistan;BMJ Open;2023-09

4. The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance;Cancer;2023-06-17

5. PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal;Current Medicinal Chemistry;2023-06-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3